Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Okwen, Mbah P ^a   Reid, Savanna ^b   Njei, Basile ^c   Mbuagbaw, Lawrence ^a  

^a YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^b ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; PLACEBO; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBODY TITER; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MIXED INFECTION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SPAIN; SYSTEMATIC REVIEW; TREATMENT DURATION; VACCINE IMMUNOGENICITY; COMPLICATION; HIV INFECTIONS; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION;

ANTI-HIV AGENTS; HEPATITIS B; HEPATITIS B VACCINES; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINATION;

EID: 84921947189     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009886.pub2     Document Type: Review

References (69)

1. Castro P, Plana M, Gonzalez R, Lopez A, Vilella A, Argelich R, et al.Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. AIDS research and human retroviruses 2009;25(12):1249-59. [PUBMED: 19943787].
2. RGonzalez, P Castro, F Garcia, M Plana, JM Bayas, S Lafuente, B Serrano, B Mora, R Argelich, JM Gatell, A Vilella. Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults. HIV Medicine 2010;11:535-539.
3. Abzug MJ, Warshaw M, Rosenblatt HM, Levin MJ, Nachman SA, Pelton SI, et al.Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. The Journal of infectious diseases 2009;200(6):935-46. [PUBMED: 19663708].
4. Alaei K, Mansoori D, Alaei A. The response to hepatitis B virus vaccine in HIV-infected patients. Archives of Iranian Medicine 2003;6(4):269-72.
5. Altuntas Aydin O, Kumbasar Karaosmanoglu H, Korkusuz R, Nazlican O. Efficacy of hepatitis B vaccine in adult HIV/AIDS patients. Hepatology International 2011;5(1):153-4.
6. Bailey C L, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. International Journal of Infectious Diseases 2008;12(6):e77-83.
7. Bunupuradah T, Ananworanich J, Pancharoen C, Petoumenos K, Prasitsuebsai W, Wongngam W, et al.Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. Vaccine 2011;29(16):2962-7. [PUBMED: 21329776].
8. Carne CA, Weller IV, Waite J, Briggs M, Pearce F, Adler MW, et al.Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine. British medical journal (Clinical research ed.) 1987;294(6576):866-8. [PUBMED: 3105779].
9. Cooper C L, Davis H L, Angel J B, Morris M L, Elfer S M, Seguin I, et al.CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005;19(14):1473-9.
10. Angel JB, Cooper CL, Clinch J, Young CD, Chenier A, Parato KG, et al.CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. Journal of immune based therapies and vaccines 2008;6:4. [PUBMED: 18700037].
11. Cooper C L, Angel J B, Seguin I, Davis H L, Cameron D W. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clinical Infectious Diseases 2008;46(8):1310-4.
12. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2008;46(8):1310-4. [PUBMED: 18444872].
13. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, et al.CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS (London, England) 2005;19(14):1473-9.
14. Cornejo-Juarez P, Volkow-Fernandez P, Escobedo-Lopez K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramirez LE. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS research and therapy 2006;3:9. [PUBMED: 16600028].
15. Cunningham C K, Rudy B J, Xu J, Bethel J, Kapogiannis B G, Ahmad S, et al.Randomized trial to determine safety and immunogenicity of two strategies for hepatitis B vaccination in healthy Urban adolescents in the United States. Pediatric Infectious Disease Journal 2010;29(6):530-4.
16. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Kauffmann RH, Leyten EM, Mudrikova T, et al.A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. The Journal of infectious diseases 2011;203(7):984-91. [PUBMED: 21266513].
17. Flynn P M, Cunningham C K, Rudy B, Wilson C M, Kapogiannis B, Worrell C, et al.Hepatitis B vaccination in HIV-infected youth: A randomized trial of three regimens. Journal of Acquired Immune Deficiency Syndromes 2011;56(4):325-32.
18. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23(22):2902-8. [PUBMED: 15780739].
19. Horster S, Laubender RP, Lehmeyer L, Ankerst DP, Eberle J, Reinert R, et al.Influence of antiretroviral therapy on immunogenicity of simultaneous vaccinations against influenza, pneumococcal disease and hepatitis A and B in human immunodeficiency virus positive individuals. The Journal of infection 2010;61(6):484-91. [PUBMED: 20875454].
20. Hwang LY, Grimes CZ, Tran TQ, Clark A, Xia R, Lai D, et al.Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. The Journal of infectious diseases 2010;202(10):1500-9. [PUBMED: 20936979].
21. Johnson D, Waddell RD, Pelton SI, Jaeger AS, Modlin JF, Yogev R, et al.Randomised trial of intradermal Mycobacterium vaccae or intradermal hepatitis B immunisation in children with HIV infection. Vaccine 1999;17(20-21):2583-7. [PUBMED: 10418906].
22. Kalinowska-Nowak A, Bociaga-Jasik M, Garlicki A, Mach T. [Efficacy of vaccination against hepatitis B in adult with HIV infection] [Skutecznosc szczepienia przeciwko wirusowemu zapaleniu watroby typu B u doroslych osob zakazonych HIV.]. Przeglad epidemiologiczny 2007;61(2):339-47. [PUBMED: 17956052].
23. Kintu K, Andrew P, Musoke P, Richardson P, Asiimwe-Kateera B, Nakyanzi T, et al.Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in uganda: Results from the first HIV vaccine trial in infants in Africa. Journal of Acquired Immune Deficiency Syndromes 2013;63(1):1-8.
24. Koblin B A, Van Benthem B H B, Buchbinder S P, Ren L, Vittinghoff E, Stevens C E, et al.Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1995. American Journal of Epidemiology 1999;150(10):1026-30.
25. Lao-Araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisanthana T, Sirisanthana V. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy. Vaccine 2011;29(23):3977-81. [PUBMED: 21473954].
26. Launay O, Van Der Vliet D, Rosenberg A R, Michel M L, Piroth L, Rey D, et al.Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: A randomized controlled trial. JAMA - Journal of the American Medical Association 2011;305(14):1432-40.
27. Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, et al.Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: A randomized, controlled trial. Journal of Infectious Diseases 2011;204(1):124-34.
28. Loke R H T, Murray-Lyon I M, Coleman J C, Evans B A, Zuckerman A J. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: An indicator of poor prognosis. Journal of Medical Virology 1990;31(2):109-11.
29. McQuillan O, Baxter J, Kingston M, Lee V, Fothergill H, Higgins S, et al.An open-label randomized study to compare the efficacy of Engerix B(registered trademark) 20 microgram vaccine with HBVaxPro(registered trademark) (40 microgram/ml) vaccine in HIV-infected patients. HIV medicine 2010;11:41-2.
30. Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, et al.Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine 2010;28(21):3672-8. [PUBMED: 20356567].
31. Mehta N, Cunningham C K, Flynn P, Pepe J, Obaro S, Kapogiannis B G, et al.Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine 2010;28(21):3672-8.
32. Miller EJ, Lee CA, Karayiannis P, Holmes S, Thomas HC, Kernoff PB. Immune response of patients with congenital coagulation disorders to hepatitis B vaccine: suboptimal response and human immunodeficiency virus infection. Journal of medical virology 1989;28(2):96-100. [PUBMED: 2738584].
33. Odaka N, Eldred L, Cohn S, Munoz A, Fields H A, Fox R, et al.Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. Journal of the American Medical Association 1988;260(24):3635-7.
34. Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, et al.Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 2010;28(34):5597-604. [PUBMED: 20600512].
35. Overton ET, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly WG, et al.GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. The open virology journal 2011;5:109-13. [PUBMED: 22043256].
36. Paitoonpong L, Suankratay C. Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scandinavian journal of infectious diseases 2008;40(1):54-8. [PUBMED: 17852939].
37. Pasricha N, Datta U, Chawla Y, Singh S, Arora SK, Sud A, et al.Poor responses to recombinant HBV vaccination in patients with HIV infection. Tropical gastroenterology: official journal of the Digestive Diseases Foundation 2005;26(4):178-82. [PUBMED: 16737046].
38. Pasricha N, Datta U, Chawla Y, Singh S, Arora SK, Sud A, et al.Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine. BMC infectious diseases 2006;6:65. [PUBMED: 16571140].
39. Ristola MA, Vuola JM, Valle M, von Reyn CF. Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects. Vaccine 2004;23(2):205-9. [PUBMED: 15531038].
40. Sasaki MG, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003;21(31):4545-9. [PUBMED: 14575766].
41. Sayad B, Alavian S M, Najafi F, Soltani B, Shirvani M, Janbakhsh A, et al.Effects of oral levamisole as an adjuvant to hepatitis B Vaccine in HIV/AIDS Patients: A randomized controlled trial. Hepatitis Monthly 2012;12(9):1-6.
42. Sellar C, Manavi K. HBV vaccine response of HIV-infected patients immunized with double dose Engerix(registered trademark) compared with vaccination response of HIV-uninfected patients vaccinated with standard dose of Engerix(registered trademark). HIV medicine 2009;10:43.
43. Thaithumyanon P, Punnahitananda S, Praisuwanna P, Thisyakorn U, Ruxrungtham K. Antibody response to hepatitis B immunization in infants born to HIV-infected mothers. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2002;85(3):277-82. [PUBMED: 12117014].
44. Thompson SC, Norris M. Immunogenicity and reactogenicity of a combined hepatitis A-hepatitis B vaccine in adolescents. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 1998;2(4):193-6. [PUBMED: 9763500].
45. Wilson CM, Ellenberg JH, Sawyer MK, Belzer M, Crowley-Nowick PA, Puga A, et al.Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Reaching for Excellence in Adolescent Care and Health. The Journal of adolescent health: official publication of the Society for Adolescent Medicine 2001;29(3 Suppl):123-9. [PUBMED: 11530313].
46. Wursthorn K, Wedemeyer H, Manns M P. Republished paper: Managing HBV in patients with impaired immunity. Postgraduate Medical Journal 2011;87(1025):223-8.
47. Alter MJ. Epidemiology of viral hepatitis and HIV co infection. Journal of Hepatology 2006;44:6-9.
48. Angel JB, Cooper CL, Clinch J, Young CD, Chenier A, Parato KG, et al.CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. Journal of Immune Based Therapies and Vaccines 2008; Vol. 6:4. [: CN-00708304].
49. Behairy El-Sayed, Mohamed El-Guindi, Ahmed El-Shaarawy, El-Sayed I. Salama, Gehan A. Sobhy. Long-term Immunogenicity of Hepatitis B Vaccinationin children. Zagazig Journal of Occupational Health and Safety December 2009;2(2):17-28.
50. BHIVA. HIV/HBV co-infection guidelines. http://www.clinical-virology.org/pdfs/BHIVA_Hep_Coinfection.pdf 2004.
51. BHIVA. British HIV Association guidelines for immunization of HIV-infected adults 2008. Human Immunodeficiency Virus Medicine 2008;9:795-848.
52. G Brook, J Main, M Nelson, S Bhagani, E Wilkins, C Leen, et al.British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. Human Immunodeficiency Virus Medicine 2010;11:1-30.
53. Diop-Ndiaye H, Toure-Kane C, et al.Hepatitis B, C seroprevalence and delta virus in HIV-1 Senegalese patients at HAART initiation (retrospective study). JMed Virol 2008;80:1332-6.
54. Gonzalez R, Castro P, Garcia F, Plana M, Bayas JM, Lafuente S, et al.Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults. HIV medicine 2010;11(8):535-9. [PUBMED: 20408890].
55. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.) 2008;336(7650):924-6. [PUBMED: 18436948].
56. Higgens JPT, Green S (editors). Cochrane Handbook for SystematicReviews of Interventions. Vol. Version 5.0.0, Chichester: TheCochrane Collaboration & John Wiley and Sons, updated February 2008.
57. Ioannidis JP, Trikalinos TA. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne 2007;176(8):1091-6. [PUBMED: 17420491].
58. Lee HC, Ko, NY, Lee NY, et al.Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in southern Taiwan, 2000-5: upsurge in hepatitis C virus infections among injection drug users. J Formos Med Assoc 2008;107:404-1.
59. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clinical Infectious Diseases 2006;43(7):904-10.
60. McQuillan O, Baxter J, Kingston M, Lee V, Fothergill H, Higgins S, et al.An open-label randomised study to compare the efficacy of Engerix B(registered trademark) 20 microgram vaccine with HBVaxPro(registered trademark) (40 microgram/ml) vaccine in HIV-infected patients. Human Immunodeficiency Virus medicine 2010; Vol. 11:41-2. [: CN-00763656].
61. Michael A. Miller, Mobeen H. Rathore. Immunization in Special Populations. Advances in Pediatrics 2012;59(1):95-136.
62. Nyirenda M, Beadsworth MB, Stephany P, et al.Prevalence of infection with hepatitis B and C virus and co infection with HIV in medical inpatients inMalawi. Journal of Infection 2008;57:72-7.
63. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
64. Sudawan Siriaksorn, Thanyawee Puthanakit, Thira Sirisanthana, Virat Sirisanthana. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy. Vaccine 12 April 2006;24(16):3095-3099.
65. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. http://www.unaids.org/en/resources/campaigns/globalreport2013/globalreport/.
66. Vandepapelière P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, et al.Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008; Vol. 26, issue 10:1375-6. [: CN-00630073].
67. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Family medicine 2005;37(5):360-3. [PUBMED: 15883903].
68. WHO. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/ 2008.
69. WHO. Immunizations, Vaccines and Biologicals: Hepatitis B. http://www.who.int/immunization/topics/hepatitis_b/en/index.html 2011.